Changes at NIH Give Political Appointees Greater Power To Fund or Block Research

The Trump administration has given notice that political appointees, rather than scientists, will ultimately decide who gets grant money from the world’s largest biomedical research funder — the federal government’s National Institutes of Health. In an Aug. 7 executive order, President Donald Trump announced that political officers would have the power to summarily cancel any…

Read More

Formulary restrictions and health outcomes: A case study in multiple sclerosis

How does formulary restrictions impact health outcomes for patients with multiple sclerosis (MS)? To answer this question, Blaylock, Van Nuys and Joyce (2025) use data 100% Medicare claims data from 2018-2022 covering patients with both prescription drug plans (PDPs) and Medicare Advantage Prescription Drug plans (MA-PDs). Individuals were categorized as above vs. below average formulary…

Read More

Owen Tripp, Included Health, talks AI

“So far AI in health care is being used to drive existing profits on workflows and increase revenue per event that patients in the end have to pay for. That’s not a win for anyone long term!” Included Health’s CEO Owen Tripp dives into the present and future use of AI, LLMs, patient self-triage and…

Read More

Novartis Tries Again in Parkinson’s, Putting Up $200M for Arrowhead’s RNAi Therapy

Novartis, which already has experience with RNA interference therapies, is now turning to this modality as a potential way to treat Parkinson’s disease. The pharmaceutical giant is licensing rights to an Arrowhead Pharmaceuticals RNAi therapy designed to inhibit production of alpha synuclein, a protein associated with Parkinson’s progression. The post Novartis Tries Again in Parkinson’s,…

Read More